Background: Life-threatening immune hemolysis may complicate minor-ABO incompatible HCT. Strategies for laboratory monitoring and proposed risk factors for hemolysis such as reduced intensity conditioning, non HLA-matched-sibling donors, CsA alone as GVHD prophylaxis, and PB rather than marrow have not previously been evaluated prospectively.

Study Design: Following fatal massive hemolysis in an index patient, we prospectively evaluated 40 consecutive, lymphocyte-replete, ABO-minor incompatible PB HCT following fludarabine/cyclophosamide(CY)-based reduced-intensity conditioning, with daily CBC, LDH, and DAT d5-15, and donor-compatible RBC transfusion to maintain the hgb > 9.5 g/dL. All donors were 6/6 HLA matched relatives who received GCSF 10 ug/d x 5 d as mobilization. GVHD prophylaxis was CsA, either alone (n=15), or combined with mycophenolate mofetil (1 g PO BID, n=18, CsA/MMF) or methotrexate (5 mg/m2 IV d 1, 3, 6, n=7, CsA/MTX). Outcomes were compared with a concurrent series of 15 T and B-cell depleted ABO-minor incompatible PB HCT following CY/TBI myeloablation.

Results: The three GVHD prophylaxis groups were similar for age, weight, gender, and CD34, B and T cell dose. Hemolysis (mean peak LDH 2445 vs 365 U/L, 9 vs 3 RBC transfusions, p<0.0001 vs no hemolysis) occurred in 5 cases; 4/15 with CsA alone, 1/18 with CsA/MMF; 3/38 sibling donor, 2/2 non-sibling donor transplants (1 parent→child with CsA/MMF, 1 child→parent with CsA alone); all 4 cases after the index case survived. Host-type RBC disappeared more quickly in cases with hemolysis (median 12 vs 138 d, p<0.001), with non HLA-matched-sibling donors (12 vs 117 d, p=0.017), and with hematologic diseases or pediatric malignancies compared to adult solid tumors (35 vs 198 d, p<0.001). A positive DAT occurred in 4/5 cases prior to hemolysis and in 28/40 cases overall; the DAT had poor positive predictive value (PPV) for hemolysis (15%) and did not impact the rate of disappearance of host-type RBC (p=0.98). Similarly, RBC eluates were positive for the relevant ABO antibody in 3/5 cases with hemolysis, and in 12/23 cases without hemolysis (PPV=20%). Donor isohemagglutinins appeared more rapidly in cases with hemolysis (9 vs 341 d, p<0.001), with non HLA-matched-sibling donors (p=0.003), and with use of CsA alone as GVHD prophylaxis (p=0.03). The allograft B-cell dose (n=22) was inversely related to the time until the DAT became positive (p<0.01) in patients who did not receive MTX, but was not associated with hemolysis. Host-type RBC disappeared more rapidly (19 vs 78 d, p=0.026), and donor-type isohemagglutinins appeared more rapidly (23 vs 434 d, p=0.04) in reduced-intensity, lymphocyte-replete HCT vs myeloablative, lymphocyte-depleted HCT treated with similar GVHD (CsA without MMF or MTX) regimens.

Conclusion: Lymphocyte-replete reduced-intensity PB HCT produce potent anti-host immune effects. Hemolysis in minor-ABO incompatible cases can be severe, and may be increased when using non HLA-matched-sibling donors or CsA alone as GVHD prophylaxis. Serial DAT monitoring has limited utility for predicting hemolysis. Daily CBC testing and aggressive transfusion support are recommended in all cases.

Author notes

Corresponding author

Sign in via your Institution